Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

= distressing pain, 4 = horrible pain and 5 = excruciating pain. The criteria for pain response are a greater than or equal to 2 point reduction in the patients' weekly PPI score from baseline and maintenance of the two point reduction for at least five consecutive weeks in the setting of a stable or decreasing weekly analgesic score compared to baseline. Patients were evaluable for pain response if their baseline PPI score was greater than or equal to one and had completed four consecutive weekly assessments of PPI and analgesic scores during the study treatment.

Data from the SPARC trial also showed that the prostate specific antigen (PSA) response rate for patients treated with satraplatin was significantly improved compared to the PSA response rate for those patients in the placebo arm. PSA response rates were 25.4 percent for the satraplatin plus prednisone arm compared with 12.4 percent for the placebo arm (p<0.001).

PSA response was analyzed using the widely adopted Bubley criteria of a decrease of PSA level by greater than or equal to 50 percent from baseline, with confirmation at least four weeks later.

"We believe the PSA response rate provides important information especially in this challenging second-line context," said Andrew Allen, Pharmion's chief medical officer and executive vice president. "To see this level of response for both pain and PSA is very encouraging and provides important additional insight on the clinical profile of satraplatin in patients with advanced prostate cancer."

Marcel Rozencweig, M.D., chief medical officer and senior vice president, drug development of GPC Biotech said: "Patients with hormone-refractory prostate cancer frequently suffer from terrible pain associated with bone metastases. The satraplatin data presented today continue to build on the progression-free survival data already presented from the SPARC trial."

The pain and PSA response analyses, in addition to the previously pres
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application ... report to their offering. Clinical ... for the detection of infectious diseases. The respiratory ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Reached in Key Lung Compartments, REINACH and ... Ltd. today announced promising,results of "first-in-man" studies ... a total of 19 healthy male,volunteers. , ... using Microdosing,for the determination of drug concentrations ...
... /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, Inc. , a ... commercializing proprietary product,candidates for the treatment ... that results from preclinical studies of ... (5-FU),and capecitabine (Xeloda(R)), an oral prodrug ...
Cached Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 2ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 3
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... (HealthDay News) -- Women, but not men, with post-traumatic ... hormone, new research shows. The hormone -- pituitary ... central nervous system activity, metabolism, blood pressure, pain sensitivity ... in the Feb. 24 issue of Nature , ...
... HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay ... pain -- an increasingly controversial treatment that has exploded ... to higher rates of permanent disability for worker,s compensation ... finds. Researchers randomly selected 725 people with low ...
... collaboration is bringing surgical patients closer to having ... trial, patients given neosaxitoxin, a new local anesthetic ... and recovered about two days sooner than those ... on this finding, Children,s Hospital Boston, a co-investigator ...
... of breast cancer survivors battle persistent fatigue, a Michigan ... a technique where physical pressure is applied to acupuncture ... can help alleviate symptoms. Gwen Wyatt will study ... two acupressure treatments on persistent cancer-related fatigue, a state ...
... - While studying one tumor-suppressing protein, Cheryl Walker,s research ... Center came across a separate surprise. They found another ... moonlighting out in the cell,s cytoplasm. Following up ... protein ATM has a second job controlling and killing ...
... San Francisco, CA February 22, 2011 The ... million in research grants as part of its Mobilizing ... populations with chronic diseases through the use of mobile-phone ... $250,000 each, will support studies on diabetes care and ...
Cached Medicine News:Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 2Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 3Health News:New long-acting local anesthetic derived from algae effectively blocks pain in surgical patients 2Health News:New long-acting local anesthetic derived from algae effectively blocks pain in surgical patients 3Health News:Acupressure shows promise in relieving fatigue in cancer survivors 2Health News:UT MD Anderson discovery wins 2010 Cozzarelli Prize 2Health News:McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants 2
... drainage from the ureteropelvic junction to ... packages. Intended for one-time use. CAUTION: ... Sof-Flex® stents must not remain indwelling ... stents must not remain indwelling more ...
... Pigtail Ureteral Stents have an exclusive ... migration. They also feature unique Tecoflex® ... savings. Each Classic Double PigTail Ureteral ... PigTail Ureteral Stent with attached braided ...
The Needle Loading Platform / Shield is designed to provide superior operator shielding during the loading of prostate implant needles with iodine or palladium seeds. It is constructed of 3/8" alumin...
The seed alignment tray aligns seeds and spacers for easy access to be picked up by the SeedVac™. It also interfaces with the seed sterilization and sorting tray for protection from radiation....
Medicine Products: